Data Platform to Accelerate Personalised Cancer Care at King's Health Partners

IDBS have announced that King’s Health Partners has deployed the Oncology Research Information System (ORIS). The ground-breaking platform is the first of its kind in production and consolidates translational medicine data from multiple sites into one system. ORIS will help uncover new avenues for research into cancer causes and personalised treatments to improve outcomes for patients in London and advance cancer research in the UK.

ORIS is based on the IDBS Enterprise Translational Medicine Solution, a product that supports cross organisation translational medicine research, accelerating development of personalised treatments. The initial ORIS deployment allows King’s Health Partners to combine clinical, genetic and tissue sample data across more than 26,000 historic breast cancer patients alongside a current feed of new, consented patients’ data direct from the clinic into the longitudinal research database.

ORIS also creates a valuable resource for pharma, biotech and diagnostic companies who are interested in collaborations in cancer research. The platform can identify patient cohorts - with similar disease characteristics - whose treatment, genetic profiles and outcomes can be followed while retaining complete patient confidentiality.

ORIS is a state-of-the-art informatics platform for examining clinical, diagnostic, pathological, biopsy, research and genomics centric data. Information is integrated from multiple sources including: an in-house Cancer Information System, the Electronic Patient Record and Diagnostic Imaging and Breast Pathology data. Disease ontologies and terminology mapping have been developed to support clinical data standards including ICD-10. All patient data is de-identified and secured within the system and made available to genomic analysis applications and analytics for patient outcomes and clustering. The design embraces flexibility and scalability that will enable King’s Health Partners and others centres of excellence to roll out the ORIS platform for use in multiple therapeutic area.